Clinical trial | Trial design | Delivery | bNAb | Highest dose given (mg/kg) | HIV-1 infected individuals given highest dose | Dosing schedule | bNAb sensitivity prescreening | Viral response | References |
---|---|---|---|---|---|---|---|---|---|
NCT02018510 | Suppression | Passive | 3BNC117 | 30 | 8 viremic individuals | One dose | Some | Viral load was reduced by mean of 1.5 log10 copies/ml (range of 0.8–2.5), and significant for 28 days | [57] |
NCT02446847 | Maintenance | Passive | 3BNC117 | 30 | 13 suppressed individuals | 2 doses 3 weeks apart, or 4 doses 2 weeks apart; ART discontinued 2 days after first dose | All | 2 infusions delayed rebound by mean of 6.7 weeks (range of 5–9) after ATI, and 4 infusions by mean of 9.9 weeks (range 3–19) | [58] |
NCT01950325 (VRC 601) | Suppression | Passive | VRC01 | 40 | 8 viremic individuals | One dose | None | Amongst responders (6/8), viral load was reduced by 1.1–1.8 log10 copies/ml, and significant for 21 days | [55] |
NCT02463227 (ACTG A5340) | Maintenance | Passive | VRC01 | 40 | 14 suppressed individuals | Dose 1 week before and 2 and 5 weeks after ART discontinuation | None | Rebound was delayed by 4 weeks (IQR 3–5) after ATI | [56] |
NCT02471326 (NIH 15-I-0140) | Maintenance | Passive | VRC01 | 40 | 10 suppressed individuals | Dose 3 days before, 2 weeks after, and each subsequent month after ART discontinuation | None | Rebound was delayed by 5.6 weeks (IQR 4.1–5.6) after ATI | [56] |
NCT02511990 | Suppression | Passive | 10-1074 | 30 | 13 viremic individuals | One dose | None | Amongst responders (11/13), viral load was reduced by mean of 1.5 log10 copies/ml (range 0.9–2.1), and significant for 27 days | [59] |